- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Regeneron’s Veopoz Receives FDA Go-Ahead
Medicine designated for the treatment of children and adults with chaple disease.
Regeneron Pharmaceuticals has confirmed the FDA approval of Veopoz (pozelimab-bbfg), designated for adult and pediatric patients one year of age and older with chaple disease, also known as CD55-deficient protein-losing enteropathy. According to a company press release, the treatment is the first and only one indicated for the potentially life-threatening gastrointestinal and cardiovascular disease.
“As the first-ever treatment for chape, Veopoz is a testament to our commitment to uncovering genetic insights and applying them to the development of effective treatments for patients in need – regardless of the prevalence of their disease,” said George D. Yancopoulos, MD, PhD, board co-chair, president, chief scientific officer, Regeneron, as per the release. “Beyond chaple, we believe Veopoz has promise in a variety of complement-mediated diseases and are driving forward several clinical programs to explore its broader potential.”
Reference: VEOPOZ™ (POZELIMAB-BBFG) RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE. Regeneron. August 18, 2023. Accessed August 21, 2023.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
